[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100495221":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":35,"centralContacts":40,"locations":48,"responsibleParty":65,"collaborators":67,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":72,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":84,"studyType":85,"phases":10,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":51,"whyStopped":10,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Barts & The London NHS Trust","OTHER",[8,14,18,22,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Cardiogenic shock and MI",null,"Patients presenting with acute myocardial infarction and cardiogenic shock who are supported medically (ie. inotropes +\u002F- intra aortic balloon pump only). N=50",[13],"Other: Observational study",{"label":15,"type":10,"description":16,"interventionNames":17},"Cardiogenic shock and MI wtih ECMO","Patients presenting with acute myocardial infarction and cardiogenic shock who are supported medically with ECMO (+\u002F- LV unloading device). N=50",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Cardiogenic shock and MI wtih Impella","Patients presenting with acute myocardial infarction and cardiogenic shock who are supported medically with Impella. N=50",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"MI without cardiogenic shock","Patients presenting with acute myocardial infarction and cardiogenic shock as a control comparator",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Non ischemic Cardiogenic Shock ie myocarditis","Patients presenting with myocarditis and cardiogenic shock as a control comparator",[13],[31],{"type":6,"name":32,"description":33,"armGroupLabels":34,"otherNames":10},"Observational study","Blood sampling and clinical data collection",[9,15,19,23,27],[36],{"name":37,"affiliation":38,"role":39},"Alastair Proudfoot","Barts Heath NHS trust","PRINCIPAL_INVESTIGATOR",[41,45],{"name":37,"role":42,"phone":43,"phoneExt":10,"email":44},"CONTACT","02037658707","alastair.proudfoot1@nhs.net",{"name":46,"role":42,"phone":43,"phoneExt":10,"email":47},"Mervyn Andiapen","mervyn.andiapen@nhs.net",[49],{"facility":50,"status":51,"city":52,"state":10,"zip":10,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Barts Health NHS trust","RECRUITING","London","United Kingdom","UK",{"type":56,"coordinates":57},"Point",[58,59],-0.12574,51.50853,{"lat":59,"lon":58},[62],{"name":63,"role":42,"phone":10,"phoneExt":10,"email":64},"Dan Jones","dan.jones8@nhs.net",{"type":66,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[68],{"name":69,"class":6},"University of Oxford","100495221","genomic-determinants-of-outcome-in-cardiogenic-shock-100495221",false,"NCT05728359","Genomic Determinants of Outcome in Cardiogenic Shock","Prospective Observational Study Investigating Genomic Determinants of Outcome From Cardiogenic Shock (GOlDilOCS)","Goldilocs","Inclusion Criteria:\n\n* All of the following are required for inclusion following screening:\n\n  * Willing to provide informed consent or appropriate consent from a nominated consultee or personal consultee\n  * Presentation within 24 hours of onset of ACS symptoms.\n  * CS can only be secondary to ACS (Type 1 MI STEMI or N-STEMI) or myocarditis\n  * Planned or completed revascularisation of culprit coronary artery\n\nCS will be defined by:\n\n* Systolic blood pressure \\\u003C90 mmHg for at least 30 minutes\n* A requirement for a continuous infusion of vasopressor or inotropic therapy to maintain systolic blood pressure \\> 90 mmHg.\n* Clinical signs of pulmonary congestion, plus signs of impaired organ perfusion with at least one of the following manifestations:\n\n  * altered mental status.\n  * cold and clammy skin and limbs.\n  * oliguria with a urine output of less than 30 ml per hour.\n  * elevated arterial lactate level of \\>2.0 mmol per litre.\n\nExclusion Criteria:\n\n* Any of the inclusion criteria not met and:\n\n  1. Unwilling to provide informed consent.\n  2. Echocardiographic evidence (recorded within 90 mins of end of PCI procedure) of mechanical cause for CS: eg ventricular septal defect, LV-free wall rupture, ischaemic mitral regurgitation.\n  3. Age \\\u003C18 and ≥80 years.\n  4. Shock from another cause (sepsis, haemorrhagic\u002Fhypovolaemic shock, anaphylaxis, etc).\n  5. Significant systemic illness\n  6. Known dementia of any severity\n  7. Comorbidity with life expectancy \\\u003C12 months.\n  8. Out-of-hospital cardiac arrest (OHCA) and any of the following:\n\n     1. No return of spontaneous circulation (ongoing resuscitation effort)\n     2. pH \\\u003C7\n     3. Without bystander CPR within 10 minutes of collapse\n  9. Arterial lactate level of \\\u003C2.0 mmol per litre.","ALL","18 Years","80 Years",{"count":82,"type":83},300,"ESTIMATED","1 Month","OBSERVATIONAL","The aim of this project is to understand the heterogeneity of both the immune consequences and treatment responses in CS. We will explore this heterogeneity through identification of transcriptomic sub-phenotypes and their association with outcomes, including therapeutic responses.",[88],"Cardiogenic Shock",[90,88,91,92,93,94],"ACS,","ECMO","Impella","Gene Expression","Endotype","2025-11-17",{"date":97,"type":98},"2025-11-18","ACTUAL",{"date":100,"type":98},"2022-08-08",{"date":102,"type":83},"2026-12-31",{"name":5,"class":6},1]